Lusutrombopag

證據等級: L5

預測適應症: 10 個

Lusutrombopag: From Thrombocytopenia (TPO-RA Therapy) to Hereditary Thrombocytopenia with Normal Platelets

One-Sentence Summary

Lusutrombopag is a thrombopoietin receptor (TPO/MPL) agonist; its original approved indication is not documented in this evidence pack (no Norway license records exist). The TxGNN model predicts it may be effective for Hereditary Thrombocytopenia with Normal Platelets, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model-generated hypothesis.

Quick Overview

Item	Content
Original Indication	Not available — no Norway license records exist for this product
Predicted New Indication	Hereditary Thrombocytopenia with Normal Platelets
TxGNN Prediction Score	99.995% (overall rank 88)
Evidence Level	L5
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

The structured original_moa field for this drug is currently a data gap (DG002, High severity). However, the model's own rationale text identifies lusutrombopag as a TPO receptor (MPL) agonist — a drug class that stimulates megakaryocyte proliferation and differentiation to increase platelet counts.

Mechanistically, this places lusutrombopag on the same pharmacological axis as platelet-production-deficiency disorders. Hereditary thrombocytopenia with normal platelets (i.e., low platelet count without accompanying structural/functional platelet defects) is, in principle, a plausible extension of TPO-receptor agonism, since the underlying deficit is quantitative (insufficient production) rather than qualitative (defective platelet function).

That said, this is a genetic/hereditary condition, and no clinical trial or published evidence currently exists to confirm efficacy or safety of a TPO-RA in this specific population. The link should be treated as a mechanistically plausible research hypothesis only, not a validated therapeutic pathway.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Norway Market Information

Lusutrombopag has no marketing authorizations recorded in Norway (total_licenses: 0, market_status: 未上市). No product/license table can be generated from the current evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/label warnings, contraindications, and DDI data are currently unavailable — flagged as DG001, Blocking severity, in the evidence pack. This gap must be closed before any Stage 1 safety assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high, and the TPO-receptor-agonist mechanism offers a plausible biological rationale, but there is zero clinical trial or literature support, no confirmed mechanism-of-action record, no safety/label data, and the drug is not currently marketed in Norway. This falls squarely in Evidence Level L5 (model prediction only) and does not meet the bar to advance past Stage 0/1.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain and parse the official label (warnings, contraindications) from the relevant regulatory authority
Resolve DG002 (High): confirm mechanism of action via DrugBank API or primary literature
Identify and document the drug's actual original approved indication(s)
Search for any preclinical or case-level evidence specific to hereditary thrombocytopenia (normal-platelet subtype) before considering further investment
Re-evaluate market/registration status if commercial availability becomes relevant to feasibility
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.